Published April 25, 2019
| Version v1
Report
Open
HAO1 inhibitor development: Structural studies with first round of follow-up compounds from TEP fragment screen - deposition 1 of 3
Description
This is part of the Open Lab Notebook intiative, to read the associated post please click here.
Notes
Funding Acknowledgment: The SGC is a registered charity (number 1097737) that receives funds from AbbVie, Bayer Pharma AG, Boehringer Ingelheim, Canada Foundation for Innovation, Eshelman Institute for Innovation, Genome Canada through Ontario Genomics Institute [OGI-055], Innovative Medicines Initiative (EU/EFPIA) [ULTRA-DD grant no. 115766], Janssen, Merck KGaA, Darmstadt, Germany, MSD, Novartis Pharma AG, Ontario Ministry of Research, Innovation and Science (MRIS), Pfizer, São Paulo Research Foundation-FAPESP, Takeda, and Wellcome.
Files
Post 9-Zenodo.pdf
Files
(273.3 kB)
| Name | Size | Download all |
|---|---|---|
|
md5:9ad1853ef5f541b3dd8faeebd312f1ca
|
273.3 kB | Preview Download |